GlassScriptPhysician profile
Avinash Vallurupalli
NPI 1457553224
$3,621.31
in general payments reported to CMS, 2019-2025
31 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $104 · 2021: $438 · 2022: $931 · 2023: $626 · 2024: $541 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,607 · Education: $44.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.91 |
| Education | $44.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $601.36 | 2021-2023 | Krystexxa |
| Amgen INC. | $551.13 | 2021-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $423.71 | 2021-2025 | |
| Vifor Pharma, INC. | $411.19 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $388.52 | 2019-2025 | Farxiga, Lokelma |
| Veloxis Pharmaceuticals, INC. | $157.55 | 2019-2023 | Envarsus |
| Medtronic Vascular, INC. | $105.81 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $86.33 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $83.33 | 2021-2025 | Lupkynis |
| Travere Therapeutics, INC. | $76.86 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.23 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $63.52 | 2021-2025 | Vafseo, Auryxia |
| Philips North America LLC | $54.75 | 2019-2024 | (Br5) Peripheral Ivus |
| Takeda Pharmaceuticals U.S.A., INC. | $47.11 | 2023-2024 | Livtencity, Gattex |
| Calliditas Therapeutics US INC. | $44.06 | 2022-2025 | Tarpeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $42.49 | 2021-2024 | Ultomiris |
| Bard Peripheral Vascular, INC. | $42.16 | 2021 | |
| Boston Scientific Corporation | $41.94 | 2023-2024 | Varithena Administration Pack |
| Cook Medical LLC | $39.88 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $37.29 | 2020-2022 | |
| Novo Nordisk INC | $33.60 | 2022-2025 | Rybelsus, Ozempic |
| Sobi, INC | $32.36 | 2025 | |
| Mallinckrodt Hospital Products INC. | $30.68 | 2024 | Acthar |
| Fresenius USA Marketing, INC. | $29.34 | 2019 | |
| Glaxosmithkline, LLC. | $28.29 | 2022-2023 | Benlysta |
| W. L. Gore & Associates, INC. | $18.35 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.92 | 2024 | |
| Scpharmaceuticals INC. | $17.55 | 2025 | |
| Opko Pharmaceuticals, LLC | $14.95 | 2023 | Rayaldee |
| Cardiovascular Systems INC. | $14.72 | 2019 | |
| Tactile Systems Technology INC | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Vallurupalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.